Mateon Therapeutics Inc (MATN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Mateon Therapeutics Inc (MATN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH63316D
  • |
  • Pages: 47
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Mateon Therapeutics Inc (Mateon), formerly OXiGENE Inc is a biopharmaceutical company developing investigational drugs for the treatment of orphan oncology indications. The company develops therapeutics to treat cancer and eye diseases; and anti-vascular drugs such as vascular disrupting agents. It is developing a product for treatment of anaplastic thyroid cancer, medullary thyroid cancer, stage IV papillary thyroid cancer, ovarian cancer, stage IV follicular thyroid cancer, and others. Mateon offers development pipeline such as CA4P and Oxi4503. The company also conducts multiple clinical trials in oncology to discover small-molecule anticancer agents belong to benzosuberene class of compound. It operates through researchers in the University of Florida and the University of Arhus on anti-angiogenic and anti-metastatic agents. Oxigene is headquartered in South San Francisco, California, the US.

Mateon Therapeutics Inc (MATN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Mateon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Mateon Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Mateon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Mateon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Mateon Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Mateon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Mateon Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12

Licensing Agreements 12

OXiGENE Enters Into Licensing Agreement With Angiogene Pharma For Neuroendocrine Tumors 12

Equity Offering 14

Mateon Therapeutics Files Registration Statement for Public Offering of Shares 14

Mateon Therapeutics Raises USD2.9 Million in Private Placement of Shares 15

Mateon Therapeutics Plans to Raise Funds trough Public Offering of Shares and Warrants 16

Oxigene Raises USD10 Million in Private Placement of Units 17

Oxigene Raises USD12 Million in Public Offering of Unit 19

Oxigene Completes Private Placement Of Preferred Stock For USD 5.8 Million 21

Oxigene Raises USD5 Million in Private Placement of Shares 22

Oxigene Completes Private Placement Of Shares For USD 1.7 Million 23

Mateon Therapeutics Inc-Key Competitors 24

Mateon Therapeutics Inc-Key Employees 25

Mateon Therapeutics Inc-Locations And Subsidiaries 26

Head Office 26

Recent Developments 27

Financial Announcements 27

Aug 14, 2018: Mateon Therapeutics reports second quarter 2018 financial results 27

May 14, 2018: Mateon Therapeutics Reports First Quarter 2018 Financial Results 28

Apr 16, 2018: Mateon Therapeutics Reports 2017 Financial Results 29

Nov 14, 2017: Mateon Provides Corporate Update and Reports Third Quarter 2017 Financial Results 31

Aug 02, 2017: Mateon Provides Corporate Update and Reports Second Quarter 2017 Financial Results 32

May 08, 2017: Mateon Provides Corporate Update and Reports First Quarter 2017 Financial Results 33

Mar 30, 2017: Mateon Therapeutics Reviews 2016 Highlights and Reports 2016 Financial Results 34

Product News 36

09/26/2017: Mateon Therapeutics Announces Termination of FOCUS Study in Ovarian Cancer 36

08/16/2017: Mateon Therapeutics Announces Results from Second Interim Analysis of CA4P Phase 2/3 FOCUS Study in Platinum-resistant Ovarian Cancer 37

04/18/2017: Mateon Therapeutics Announces Encouraging Results from First Interim Analysis of Phase 2/3 FOCUS Study in Platinum-resistant Ovarian Cancer 38

01/20/2017: Mateon Therapeutics to Present Data on Study OX4218 in Neuroendocrine Tumors at ASCO Gastrointestinal Cancers Symposium 39

Clinical Trials 40

Jan 08, 2018: Mateon Announces New Preclinical Data Demonstrating Enhanced Tumor Immune Responses When CA4P Is Given In Combination With Checkpoint Inhibitors 40

Dec 05, 2017: Mateon Announces Preclinical Data Indicating Enhanced Tumor Immune Response of CA4P with Checkpoint Inhibitor 41

Aug 01, 2017: Mateon Therapeutics Completes Enrollment in Phase 2 Portion of FOCUS Study of CA4P for Platinum-Resistant Ovarian Cancer 42

Jun 28, 2017: Mateon Therapeutics Announces New Interim Preclinical Data on CA4P in Combination with Checkpoint Inhibitors 43

Jun 12, 2017: Mateon Therapeutics Provides Update on Ovarian Cancer Clinical Trial Program 44

Apr 20, 2017: Mateon Announces Initiation of Investigator-Sponsored Phase 1 Study of CA4P in Combination with Everolimus in Neuroendocrine Tumors 45

Feb 13, 2017: Mateon Therapeutics Announces Initial Pre-clinical Data on Combination of CA4P with Checkpoint Inhibitors 46

Appendix 47

Methodology 47

About GlobalData 47

Contact Us 47

Disclaimer 47

List of Figures

Mateon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Mateon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Mateon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Mateon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Mateon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Mateon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Mateon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Mateon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Mateon Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

List of Tables

Mateon Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Mateon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Mateon Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Mateon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Mateon Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Mateon Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

Mateon Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

OXiGENE Enters Into Licensing Agreement With Angiogene Pharma For Neuroendocrine Tumors 12

Mateon Therapeutics Files Registration Statement for Public Offering of Shares 14

Mateon Therapeutics Raises USD2.9 Million in Private Placement of Shares 15

Mateon Therapeutics Plans to Raise Funds trough Public Offering of Shares and Warrants 16

Oxigene Raises USD10 Million in Private Placement of Units 17

Oxigene Raises USD12 Million in Public Offering of Unit 19

Oxigene Completes Private Placement Of Preferred Stock For USD 5.8 Million 21

Oxigene Raises USD5 Million in Private Placement of Shares 22

Oxigene Completes Private Placement Of Shares For USD 1.7 Million 23

Mateon Therapeutics Inc, Key Competitors 24

Mateon Therapeutics Inc, Key Employees 25

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Mateon Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17500
Site License
USD 500 INR 35000
Corporate User License
USD 750 INR 52500

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com